A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain (CYDEPS)

C

Cymra Life Sciences

Status and phase

Completed
Phase 2
Phase 1

Conditions

Back Pain
Pain, Back
Pain, Neck
THC
Chronic Pain
Pain, Chronic
CBD
Neck Pain
Pain

Treatments

Drug: Cybis™ 10:25 THC:CBD oil

Study type

Interventional

Funder types

Industry

Identifiers

NCT04976738
CYM-001-21

Details and patient eligibility

About

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.

Full description

This is a non-randomised, single arm, open-label study of Cybis™ 10:25 in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25. The purpose of the study is to demonstrate the safety and tolerability of Cybis™ 10:25 in participants with moderate to severe chronic back or neck pain that is unresponsive to over-the-counter non-opioid analgesics. Participants will undergo a screening visit, then seven clinic visits (Day 1, 2, 8, 15, 22, 29, and 35). Cybis™ 10:25 will be administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.

Enrollment

28 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged over 18 years and less than 75 years of age on the date of the Screening Visit;
  • Have back and or neck pain of at least three months duration;
  • Have an average back or neck pain score of between 5 and 9 on a 10-point visual analogue pain scale;
  • Have failed to achieve self-reported satisfactory pain relief using over-the-counter paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs);
  • Are willing to cease all current pain medications 14 days prior to commencing Cybis™ 10:25, and for the duration of the study (except as allowed under rescue medication); Note: Pain medication may include opioids (including but not limited to paracetamol+codeine combinations, codeine, tramadol, tapentadol, buprenorphine), NSAIDs and other co-analgesic medications (such as anti-epileptics, antidepressants, clonidine) and/or any other pain medications.
  • Agree to cease any dietary or herbal supplements (e.g. St John's Wort) fourteen days prior to commencing Cybis™ 10:25, and for the duration of the study;
  • Are willing to cease driving a car or operating heavy machinery from the day of first dosing to seven days after administration of the last dose of Cybis™ 10:25;
  • Agree to use contraception throughout the study, and for one month after the last dose of Cybis™ 10:25 is administered (if reproductive age female) or three months after the last dose of Cybis™ 10:25 is administered (if male); Note: women of childbearing potential must have a negative serum or urine pregnancy test prior to entry into the study. For women, adequate contraception is a double barrier method for the duration of the study and for 30 days post the last study dose. For men, barrier contraception is required for the duration of the study and for 3 months after the last study dose.
  • Agree to adhere to the study protocol; and
  • Are willing and able to provide written informed consent.

Exclusion criteria

  • Are pregnant or breastfeeding;
  • Currently using marijuana or other medicinal cannabis products; Use of medical cannabis products > 6 months prior to Screening is acceptable;
  • History of cannabis use disorder (score of 8 or higher on The Cannabis Use Disorder Identification Test - Revised (CUDIT-R);
  • Current or previous allergies or allergic responses to any of the components of the study treatment (e.g., THC, CBD, MCT);
  • Current or previous allergies or allergic responses to any of the components of the rescue medication (e.g. paracetamol, ibuprofen, aspirin, other NSAIDs);
  • Significant cardiac disease (e.g. poorly controlled hypertension, symptomatic ischaemic heart disease, symptomatic heart failure);
  • Chronic liver disease with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper level or normal limits;
  • Chronic renal impairment with eGFR <30mL/min;
  • Taking sildenafil or other PDE5 inhibitors;
  • Being treated with known inducers/inhibitors of CYP3A4, in particular clarithromycin, rifampicin, azole antifungals, antiretroviral agents, anticonvulsants (phenytoin, carbamazepine), SSRI within 30 days of study commencement; Use of such enzyme-altering agents is prohibited throughout the study.
  • Have a major psychiatric disorder (e.g. schizophrenia, psychosis, bipolar disorder, but not anxiety or depression), by history or examination;
  • Are currently using any illicit drug (including, but not limited to, amphetamines, cocaine);
  • Have a history of other substance abuse disorder (as defined by DSM-5);
  • Have active substance abuse disorder (alcohol, illicit drugs);
  • Other clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, or vital signs, which in the opinion of the Investigator, may put the participant at risk of adverse events;
  • Other chronic disease (other than chronic pain) that in the opinion of the Investigator may impact the safety, efficacy and/or pharmacokinetics of the study drug;
  • Are currently participating in, or have participated (in the last 30 days) in a drug or device clinical trial;
  • Currently using opioids (including but not limited to paracetamol+codeine combinations, codeine, tramadol, tapentadol, buprenorphine) and not willing to cease opioids for the duration of the study;

COVID-19 vaccination within two (2) weeks of study assessments:

  • Study assessments should not commence until two (2) weeks after a COVID-19 vaccination dose (first, second or booster dose)
  • Subsequent COVID-19 vaccination doses (first, second or booster dose) should not be administered until 7 days after Day 35 study assessments have been completed.
  • Back and/or neck surgery within three (3) months of Screening; or
  • Have history of metastatic cancer or are currently receiving treatment for cancer.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

28 participants in 1 patient group

Treatment arm: Cybis™ 10:25 THC:CBD oil
Experimental group
Description:
Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
Treatment:
Drug: Cybis™ 10:25 THC:CBD oil

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems